Related Experiment Videos
[Experimental study on TNF-alpha linked percutaneous isolated hepatic chemoperfusion (PIHP)]
1First Dept. of Surgery, Kobe University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 15, 1998
Summary
Isolated hepatic perfusion with TNF-alpha and an anti-TNF-alpha antibody significantly reduced systemic exposure to TNF-alpha in a canine model. This combination therapy shows promise for liver cancer treatment.
Area of Science:
- Oncology
- Immunology
- Surgical Innovation
Context:
- High-dose tumor necrosis factor-alpha (TNF-alpha) is explored for locoregional chemotherapy in hepatic malignancies.
- A novel hepatic venous isolation and charcoal hemoperfusion (HVI.CHP) system offers minimally invasive, high-dose liver chemotherapy.
- Systemic toxicity from TNF-alpha limits its therapeutic application.
Purpose:
- To evaluate the efficacy of combining HVI.CHP with anti-TNF-alpha antibody to mitigate systemic TNF-alpha exposure during hepatic arterial infusion (HAI).
Summary:
- Beagles received HAI of TNF-alpha, with one group also receiving an anti-TNF-alpha antibody via the hepatic venous outflow line.
- Systemic TNF-alpha levels (Cmax and AUC) were significantly lower in the group treated with the antibody compared to the control group.
- The anti-TNF-alpha antibody effectively reduced systemic exposure to TNF-alpha.
Impact:
- HVI.CHP in conjunction with anti-TNF-alpha antibody demonstrates a viable strategy to reduce systemic toxicity.
- This approach may enhance the safety and efficacy of TNF-alpha-based chemoperfusion for liver tumors.